anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As a consequence of the COVID-19 pandemic, and after consultation with the appropriate research oversight, regulatory and monitoring entities, screening and enrollment was been placed on temporary administrative hold as of 3 17 2020. As the pandemic has continued, we have reviewed our data and decided to close the study to enrollment and proceed to our analyses of findings.

RESEARCH DESIGN: A prospective cohort study of Veterans will be conducted to determine if the previously-identified specific actigraphy-based measurements highly associated with suicidal ideation in non-Veterans will predict suicidal ideation, suicidal behavior, and/or rehospitalization in Veterans.

METHODS: An analysis of Veterans admitted to the Bedford, Massachusetts VAMC acute psychiatry unit will be conducted. The primary analysis will focus upon Veterans with current suicidal ideation or recent suicidal behavior (SI/SB) who do not have a primary psychotic disorder, Alzheimer's, or Parkinson's disease, and who are not undergoing alcohol detoxification. A separate analysis will be conducted of patients undergoing alcohol detoxification, half with SI/SB and half without SI/SB. Participants will wear a small, unobtrusive, wristwatch-like actigraph on their nondominant wrist, and complete self-rated and clinician-rated assessments of suicidal ideation, as well as self-rated assessments of the severity of other psychiatric symptoms. A Resiliency Index (RI) will be calculated using nonlinear dynamic analysis of the amplitude of movements over time frames from 6 minutes - 2 hours. These time frames are the periods for which a clear structure to the movement data is evident, with patients with suicidal ideation showing less variation in amplitude than patients without suicidal ideation. If medications given for alcohol detoxification are determined to not interfere with the RI, then a secondary analysis will examine the entire sample of Veterans. One Aim will focus upon determining whether the original Resiliency Index or alternative movement data indices, such as one based on the change in the movement data over the hospitalization, predicts the presence and severity of suicidal ideation among Veteran inpatients. This aim will also examine the sensitivity and specificity of the RI for detecting the presence of any suicidal ideation, and of substantial suicidal ideation. (In non-Veterans, the RI showed a sensitivity of 72% and a specificity of 100% for detecting any suicidal ideation, and 86% and 88%, respectively, for detecting substantial ideation). In addition, the investigators may determine whether the RI predicts subsequent suicidal behavior or rehospitalization over different time periods within the original 12 month followup period, alone or combined with data about symptom severity, past history, and the present hospitalization.
The invention pertains to the field of medicine and relates to a method for suppressing the growth of tumors, which comprises blocking the pathway of "human fibroblast growth factor / human fibroblast growth factor receptor 1 (domains II and IIIc)", and to a method for diagnosing malignant neoplasms. This pathological pathway leads to an excessive proliferation of tumor cells and to the formation of new vessels accompanied by the growth of primary tumors and metastases. This pathway also represents an independent mechanism of tumor resistance to preparations acting on other pathological pathways. Blocking the pathway of "fibroblast growth factor / fibroblast growth factor receptor 1" using various substances that neutralize the receptor by bonding only with domains II and IIIc thereof results in the interruption or slow-down of tumor growth. This receptor can also be used as a target for the targeted delivery of diagnostic agents as it is present in large amounts in the cells of numerous tumors. The invention is advantageous in that it makes it possible to develop new agents for diagnosing and treating diseases related to excessive proliferation and neovascularization
PURPOSE:To provide a new compound having excellent hypoglycemic activity and blood lipid-reducing activity, also low in side effects, thus useful as an anti-diabetic agent, etc. CONSTITUTION:The objective compound of formula I (R<1> and R<2> are each H, halogen, etc.; X is N or CH; double line made up of dotted and solid lines denotes single bond or double bond; A is heterocycle such as of formula II, III, etc.; n is 1-4), e.g. 4-{2-[1-(alpha,alpha,alpha-trifluoro-4-tolyl)-2-imidazolidin-3- yl]ethoxy}benzylidene-2,4-thiazolidinedione. The compound of the formula I can be obtained by reaction between a compound of formula IV and benzaldehyde in a solvent in the presence of triphenylphosphine and diethyl azodicarboxylate to produce a compound of formula V, which is, in turn, reacted with 2,4-thiazolidinedione in a solvent in the presence of a basic compound such as triethylamine at 60-140 deg.C for 1-24hr.
After nearly 40 years of research, a microbiota was discovered and named JCL. With special formula and treatment, a new principle therapy to build up the inherent ability of the immune system can activate cell molecules to be more active, stronger, larger, and faster to treat and repair the affected area, The marks on the affected area can be disappeared in a short time and the original appearance can be restored, the stomach and duodenal ulcers can be completely healed, and the stomach will become very healthy and strong and never get sick again. Gastroesophageal reflux is a disease caused by unhealthy gastric secretion disorders. After taking this product for three weeks, the gastric acid secretion disorders can be regulated to restore the original function. Gastroesophageal reflux can be completely cured and the user never needs to take it again nor get sick. I suffered from duodenal ulcer for forty years and recovered after taking this product for forty-five days. I have not relapsed for seven years since healed, and I have not even felt any discomfort. The product can effectively inhibit the activity of cancer cells, cause the death of cancer cells, and further activate the phagocytic power of macrophages to kill cancer cells. At present, these three diseases cannot be cured by taking medicine in the whole world. The above statement is completely true and not exaggerated. The present invention is a world-leading technology to be the pride of Taiwan.
For the first time, the present invention provides isolated, substantially pure, and/or recombinantly produced pANCA associated with ulcerative colitis (UCpANCA and UCpANCA material) as well as polynucleotides encoding the UCpANCA, UCpANCA material and UCpANCA polypeptides of the present invention.  Using the phage display technique, immunoglobulin gene repertoires biased for the immunoglobulin genes utilized by pANCA seropositive UC patients have been isolated, amplified, randomly re-combined to generate phagemid expression vector libraries encoding DNA homologs of the gene repertoire. Methods are provided for enriching these libraries to create libraries of VH- and VL-encoding DNA homologs having immunoreactivity of UCpANCA antigen. Also provided are methods of screening the libraries of the present invention for UCpANCA and UCpANCA material. These libraries may be encapsulated in phage particles or in cells. Methods and kits are also provided for screening for UCpANCA in a sample and isolating UCpANCA antigen.
The present invention presents pharmaceutical compositions and methods of use of those compositions to treat colic in horses and other vertebrates, including humans. In a preferred embodiment, a first composition, made with an anti-spasmodic (such as dicyclomine), an analgesic, an anti-inflammatory, and an anxiolytic (such as alprazolam), is administered via rectal suppository or other route. In addition, an intestinal smooth muscle relaxant, or a nitric oxide donor may be used in the composition. Alternatively, a second composition is made of an analgesic and an anxiolytic, and, optionally, one or more components selected from an anti-spasmodic, an anti-inflammatory, an intestinal smooth muscle relaxant, and a nitric oxide donor. In another preferred embodiment, administration of the first composition is followed by administration of a second composition that is a laxative. Typically, the laxative is administered from about 10 minutes to about 2 hours after administration of the first composition, and preferably is by oral administration. Alternate anti-spasmodics, analgesics, anti-inflammatories, and anxiolytics may be used beneficially as well. For non-spastic colics, the anti-spasmodic may be eliminated. The use of nitric oxide donors are particularly beneficial in necrotizing enterocolitis.
Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
Primary cilla are finger-shaped structures assembled by intraflagellar transport and function as a sensor to mechanical and chemical signals. Deficiency of cilla relates with progress of polycystic kidney disease and determination of the mechanism of deficiency of cilla is very important in understanding polycystic kidney disease. According to the present invention, the function of IFT46 has been found in the kidney epithelial cells and mouse kidney. When IFT 46 is reduced, cilla are shortened and the path of MAPK is activated to increase the growth of cells in the kidney epithelial cells. In addition, a decrease in IFT46 expression affects the PC2 activity controlled by the flow sensing. An abnormal condition caused by a decrease in IFT46 expression induced rapid cysts in a 3D culture system. In fact, the level of IFT46 mRNA and protein is dramatically reduced in the cilla-deficient human polycystic kidney tissue as compared to the normal kidney. Based on such results, a mouse having specifically reduced IFT 46 in its kidney is made according to the present invention. Deficiency of IFT46 genes in the kidney induced a severe polycystic kidney phenotype lost with cilla and mTOR path activity. Such results suggest that abnormality of cilla caused by IFT46 deficiency functions as an etiological factor during the progress of polycystic kidney disease.
BACKGROUND: Keloid is a skin disorder that results from excessive fibrous tissue growth in the area of the initial trauma. Treating keloids can be challenging since the success of various treatments varies from one study to another. Triamcinolone acetonide injection, a standard treatment, can cause undesirable side effects. Meanwhile, the effectiveness of existing topical therapies for keloids is not always reliable. The pro-inflammatory, pro-proliferative, and pro-fibrotic effects of angiotensin II in human skin contribute to keloid formation. Losartan potassium, an angiotensin II blocker, has the potential to act as an anti-keloid agent. Due to the thicker skin structure of a keloid and ease of application, ethosome gel is chosen as a safe and comfortable carrier for losartan potassium, making it a good choice for treating keloids.
METHODS: In this randomised clinical trial, 46 adults with keloids were divided into two treatment groups. One group of 23 participants received 5% losartan potassium loaded in ethosomal gel, while the other group of 23 participants received intralesional injections of 10% triamcinolone acetonide. Over 12 weeks, changes in POSAS 3.0 scores, degree of erythema and pigmentation, surface area, thickness, and pliability of the keloids will be measured at four different times: baseline, 4 weeks, 8 weeks, and 12 weeks. Statistical analysis will be conducted using SPSS software version 24, with a significance level of p < 0.05.
DISCUSSION: Losartan potassium is believed to be beneficial for keloid management because it inhibits the angiotensin II receptor, which plays a role in inflammation, proliferation, and fibrosis. This study examines the efficacy of 5% losartan potassium loaded in ethosomal gel for human keloids.
TRIAL REGISTRATION: Clinicaltrial.gov identifier NCT05893108 . Registered on 7 June 2023.
Breast cancer treatment has been accompanying advances in technology, surgeries are more conservative, however postoperative complications are still observed. At early postoperative period, the most common operative wound complications are seroma, infection and necrosis. Shoulder dysfunctions are a frequent complication and difficult women to return to their activities. There is no consensus regarding the onset and type of exercise in postoperative period. Thus, the objective of this study is to compare the active no-limited mobilization with limited mobilization in the immediate post operatory at the incidence of wound complications in women submitted to surgery for the treatment of breast cancer.

It's a randomized clinical trial that will include women aged 18 years or older, submitted a curative surgery for breast cancer at Hospital do Câncer III (HCIII-INCA) located in Rio de Janeiro. All patients admitted for surgical treatment at the institution and during the study period will be evaluated for eligibility criteria. Those considered eligible for the study will be clarified regarding the objectives, treatment groups, adverse effects and non-compulsory participation of the study. Upon acceptance to participate, they will be allocated to the respective intervention groups. Group 1 - upper limbs no-limited movement with amplitude above 90º for flexion and abduction of shoulder; Group 2 - upper limbs limited movement at maximum 90º amplitude flexion and abduction of shoulder, until withdrawal surgical points.
PURPOSE: To develop and evaluate a transorbital endoscopic approach to the foramen rotundum to excise the maxillary nerve and infraorbital nerve branch.
METHODS: Cadaveric dissection study of 10 cadaver heads (20 orbits). This technique is predicated upon 1) an inferior orbital fissure release to facilitate access to the orbital apex and 2) the removal of the posterior maxillary wall to enter the pterygopalatine fossa (PPF). Angulations along the infraorbital nerve were quantified as follows: the first angulation was measured between the orbitomaxillary segment within the orbital floor and the pterygopalatine segment suspended within the PPF, while the second angulation was taken between the pterygopalatine segment and maxillary nerve as it exited the foramen rotundum. With refinement of the technique, the minimum amount of posterior maxillary wall removal was quantified in the final 5 cadaver heads (10 orbits).
RESULTS: The mean distance from the inferior orbital rim to the foramen rotundum was 45.55 ± 3.24 mm. The first angulation of the infraorbital nerve was 133.10 ± 16.28 degrees, and the second angulation was 124.95 ± 18.01 degrees. The minimum posterior maxillary wall removal to reach the PPF was 11.10 ± 2.56 mm (vertical) and 11.10 ± 2.08 mm (horizontal).
CONCLUSIONS: The transorbital endoscopic approach to an en bloc resection of the infraorbital nerve branch up to its maxillary nerve origin provides a pathway to the PPF. This is relevant for nerve stripping in the context of perineural spread. Other applications include access to the superior portion of the PPF in selective biopsy cases or in concurrent orbital pathology.
A shaving oil wipe made from combining a wipe or wipe-type product with natural fats or oils for shaving. The shaving oil wipe includes a package unit and at least one shaving oil wipe received in the package unit. The shaving oil wipe includes a fibrous carrier and a shaving oil composed of oils from either natural or synthetic sources. The shaving oil is disposed on the surface of the fibrous carrier or impregnated on the fibrous carrier. When the shaving oil of the shaving oil wipe is applied on a user's skin, a layer of oil is produced on the skin to provide good lubrication for shaving. Convenience of usage, good portability, and efficient application of shaving oil to skin are advantages.
The innate immune molecule NLR family CARD domain-containing 5 (NLRC5) plays a significant role in endometrial carcinoma (EC) immunosurveillance. However, NLRC5 also plays a protumor role in EC cells. Mismatch repair gene deficiency (dMMR) can enable tumors to grow faster and also can exhibit high sensitivity to immune checkpoint inhibitors. In this study, we attempted to determine whether NLRC5-mediated protumor role in EC is via the regulation of dMMR. Our findings revealed that NLRC5 promoted the proliferation, migration, and invasion abilities of EC cells and induced the dMMR status of EC in vivo and in vitro. Furthermore, the mechanism underlying NLRC5 regulated dMMR was also verified. We first found NLRC5 could suppress nuclear factor-kappaB (NF-κB) pathway in EC cells. Then we validated that the positive effect of NLRC5 in dMMR was restricted when NF-κB was activated by lipopolysaccharides in NLRC5-overexpression EC cell lines. In conclusion, our present study confirmed the novel NLRC5/NF-κB/MMR regulatory mechanism of the protumor effect of NLRC5 on EC cells, thereby suggesting that the NLRC5-mediated protumor in EC was depend on the function of MMR.
Single centre, double-blind, randomised, placebo-controlled, rising multiple dose study in four sequential groups of healthy male and female subjects. Eligible subjects were admitted to the Human Pharmacology Unit (UFH)on the day prior to receiving the first study medication. Starting in the morning of Day 1 (first dose), subjects received BIA 6-512/Placebo thrice daily until the morning of Day 5 (last dose). Concomitantly with the morning dose of BIA 6-512/Placebo on Day 4, a levodopa/benserazide 200/50 mg (Madopar® 250) single-dose was administered. On Day 5, a Madopar® 250 single-dose and a nebicapone 150 mg single-dose were administered concomitantly with the morning dose of BIA 6-512/Placebo. In the morning of Day 4 and Day 5, products were administered in fasting conditions of at least 8 hours and subjects remained fasted until 2 h post-dose. Subjects were resident in the UFH from admission (Day 0) until at least 24 h post last dose (Day 6); then, they were discharged and returned for the follow-up visit.
OBJECTIVES: Non-immune hydrops fetalis (NIHF) is the pathological accumulation of fluids in fetal compartments, without maternal isoimmunization. Fetal interventions (e.g. shunting, fetal paracentesis, fetal thoracocentesis, fetal pleurodesis) are used to alleviate fluid accumulations, but the outcome is uncertain because the underlying causes of NIHF vary. We aimed to explore the etiology and long-term outcome of NIHF after fetal intervention.
METHODS: This was a retrospective review of fetuses with NIHF, defined by the presence of fetal ascites, pleural or pericardial effusion, skin edema or cystic hygroma, or a combination of these features, who underwent intervention at our institution during the period 2012-2021. Clinical surveillance, genetic analysis and viral infection screening were used to define the etiology. Chart reviews and telephone interviews were conducted to assess the long-term outcomes.
RESULTS: In total, 55 fetuses were enrolled and 46 cases had final follow-up data after delivery. Etiology was identified in 33 cases, including four for which the underlying causes were not identified initially using small-gene-panel tests but which were later diagnosed with monogenic disorders by whole-exome sequencing (WES). Twenty-three cases with follow-up survived, having a follow-up period of 2-11 years at the time of writing, of which 17 were healthy. All 11 cases initially presenting as congenital chylothorax survived with favorable outcome.
CONCLUSIONS: The etiologies of NIHF are heterogeneous, and the long-term (spanning 2-11 years) outcome of fetal intervention varies, according to the underlying etiology, with cases caused by congenital chylothorax having the best prognosis. Genome-wide tests, such as WES, may be helpful in determining the underlying condition in cases caused by a genetic disorder, and this may affect fetal therapy approaches in the future. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
This was a cross-sectional study investigating suprascapular nerves in the painful shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
Incorporation of a microbial cell suspension throughout a fibrous network provides a physical environment that allows greater removal of water during lyophilization or desiccation thereby yielding a device with improved stability and recovery of viable microbial cells. Strands of appropriate fibers in a tightly knit network absorb aqueous cell suspensions by a capillary effect rather than absorption. When vapor pressure is decreased by vacuum during lyophilization or by air moved during desiccation, the surface tension is affected at the fiber/water interface, which results in increased water removal, by a “reverse capillary” effect. Thus bound and free water removal is increased. Therefore, incorporation of the use of a network of fibers in conjunction with a preservation matrix containing sensitive microbial cells provides a means of producing a preserved product with increased stability at both extreme and routine storage temperatures and greater efficacy for the end user. The invention also provides a means for recovery of viable microbial cells by direct inoculation to solid or liquid culture media as recommended for use in performance or quality control testing of culture media, stains, identification kits, maintenance of stock cultures and in the evaluation of bacteriological procedures. Additionally, the device can be used to mimic clinical specimens in clinical or industrial proficiency testing surveys that test the ability of laboratory technologists to properly perform diagnostic procedures.